Assetmark, Inc Syndax Pharmaceuticals Inc Transaction History
Assetmark, Inc
- $45.6 Billion
- Q3 2025
A detailed history of Assetmark, Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Assetmark, Inc holds 40 shares of SNDX stock, worth $664. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40Holding current value
$664% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
253Shares Held
99.8MCall Options Held
1.41MPut Options Held
737K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$142 Million11.08% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$131 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.49MShares$91.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.14MShares$85.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.26MShares$70.7 Million0.13% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $940M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...